logo
US trade talks to stick to terms agreed earlier

US trade talks to stick to terms agreed earlier

Hindustan Times2 days ago
India and the United States are intensely engaged to conclude a mutually beneficial early trade deal by the end of this month, 'strictly' within the bilaterally agreed framework of March 29, irrespective of the ongoing political rhetoric and independent of their strategic relationships with other countries, people in the know said on Sunday. he two countries finalised the detailed terms of reference (ToR) to enter into negotiations of the bilateral trade agreement (BTA) on March 29 during their first physical round of talks in New Delhi. (PTI)
It may be part of the negotiations that India and the US may purchase and sell more energy as an outcome of the deal. But the agreed framework does not proscribe either nation from purchasing oil and gas from any third country of its choice, they said, requesting anonymity.
The two countries finalised the detailed terms of reference (ToR) to enter into negotiations of the bilateral trade agreement (BTA) on March 29 during their first physical round of talks in New Delhi. Later, on April 22, US Vice President JD Vance officially announced the finalisation of the ToR for bilateral 'trade negotiations' during his India visit, and called it 'a vital step toward a final deal' between the two nations in a post on X that day.
ToR is a set of bilaterally agreed road map for BTA negotiations. Both sides have concluded five physical rounds of negotiations and several virtual discussions within that framework. In the process, the two sides have already reached some common ground, substantial enough to announce an interim deal, they said.
'We are engaged through virtual mode as on date and likely to iron out remaining differences when the American negotiating team visits India for the sixth physical round this month,' one of the people cited above said. The US negotiating team is expected to land in New Delhi on August 24 to participate in the sixth round of talks from August 25. According to the people, some concrete outcomes are expected after the successful conclusion of the sixth round towards the end of August, despite US President Donald Trump's recent statements and tariff actions against India.
Trump on July 30 announced punitive tariffs on Indian goods through a post on Truth Social. The announcements involved 25% on Indian goods shipped to America and an unspecified levy for purchasing Russian oil. Trump's reaction was an outcome of India refusing to budge on retaining protections for its agriculture, dairy and micro, small and medium enterprises (MSME) sectors from unfettered American imports.
Another factor behind Trump's reaction was India importing almost one-third of its crude oil requirements from Russia. About that, Trump on July 31 said on Truth Social: 'I don't care what India does with Russia… They can take their dead economies down together, for all I care.'
According to the US Energy Information Administration's (EIA) country analysis updated on February 6, 2025, Russia was the primary source of India's crude oil and condensate imports in 2023, accounting for about 39% of its total imports, followed by Iraq (19%), Saudi Arabia (16%), United Arab Emirates (5%) and the US (4%). India imported 4.5 million barrels a day (b/d) of crude oil and condensate in 2023, it said.
'In 2022, after the United States and EU imposed sanctions on Russia, India began purchasing Russia's crude oil at a discount, increasing its imports more than sixfold to 740,000 b/d,' the report said.
Energy hungry India, which is the world's third largest importer after the US and China, imports over 87% of the crude oil it processes. 'Economical and reliable energy supply is the top priority of India's energy security, and heavily discounted crude from Russia meets both the requirements. Our energy sourcing is diversified, involving 39 countries. We have recently increased energy imports from the US and this may go up further depending on commerciality. But our sourcing from Russia would not stop under any external pressure. We are not bound by any unilateral sanction as we follow the UN sanction,' a second person said.
Energy security is India's key concern and the US is endowed with the natural resource. The proposed BTA may have some definite commitments for enhanced energy imports from the US, depending on the long-term commercial viability, the people mentioned above said. 'But the deal cannot and will not restrict India's freedom in pursuing its independent energy sourcing. We are buying crude oil from about 40 countries, including the US, the Middle East and Russia. And the policy of diversified sourcing will continue,' the first person said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

New 'Khalistan embassy' in Canada threatens India-Canada ties again
New 'Khalistan embassy' in Canada threatens India-Canada ties again

Business Standard

time2 minutes ago

  • Business Standard

New 'Khalistan embassy' in Canada threatens India-Canada ties again

Just as India and Canada were making cautious moves to improve strained ties, visuals of an 'Embassy of the Republic of Khalistan' on Canadian soil have risked derailing hard-earned diplomatic progress. Radical Sikh groups in British Columbia have established what they describe as the 'Embassy of the Republic of Khalistan'. Photographs accessed by India Today show that the self-proclaimed embassy is located inside a section of the Guru Nanak Sikh Gurdwara in Surrey. The same gurdwara was once led by Hardeep Singh Nijjar, a pro-Khalistan figure whom Indian authorities had labelled a terrorist. Nijjar was shot dead in 2023 in the gurdwara's car park, setting off a chain of events that pushed India-Canada relations into a deep freeze. The announcement of the so-called 'embassy' coincides with preparations for a 'Khalistan referendum' organised by Sikhs for Justice (SFJ), a group banned in India. According to reports, Indian security agencies are keeping a close watch. Diplomatic thaw under threat The development comes at a time when ties between the two countries had shown tentative signs of a thaw. Prime Minister Narendra Modi and Canada's newly-elected Prime Minister Mark Carney met face-to-face during the G7 summit earlier this year — their first such meeting since tensions escalated. Both sides had indicated a willingness to move beyond the fallout from Nijjar's killing and the allegations made by former Canadian Prime Minister Justin Trudeau, who had accused the Indian government of involvement in the murder — a charge New Delhi has firmly denied. Canadian intelligence backs India's security concerns India has long raised concerns about Khalistani groups using Canadian soil as a safe haven for promoting separatist ideology, fundraising, and plotting acts of violence. It has consistently criticised Canadian authorities for alleged inaction. In a notable shift, Canadian authorities have acknowledged these concerns. In June 2025, the Canadian Security Intelligence Service (CSIS) officially recognised the threat posed by Khalistani extremists operating within Canada. Its annual report stated: 'Khalistani extremists continue to use Canada as a base for the promotion, fundraising or planning of violence primarily in India.' While no attacks linked to Canada-based Khalistani extremists (CBKEs) occurred in 2024, CSIS warned that such actors remain active in global financing and operational planning. This marked the first time the Canadian government has officially used the term 'extremism' in the context of the Khalistan movement. CSIS described Canada-based Khalistani extremists as a core element of the country's politically motivated violent extremism (PMVE) threat. According to the agency, PMVE groups aim to use violence to create new political systems or structures, often through cross-border efforts. Khalistani actors, the agency warned, continue to engage in 'planning, financing and facilitating attacks globally' in pursuit of a separate Khalistan state, primarily carved out of India's Punjab region.

Britannia Q1 profit misses estimates, sees early signs of urban recovery
Britannia Q1 profit misses estimates, sees early signs of urban recovery

Business Standard

time2 minutes ago

  • Business Standard

Britannia Q1 profit misses estimates, sees early signs of urban recovery

Britannia Industries posted first-quarter profit below estimates on Tuesday, but the Indian biscuit maker said urban consumption - dull for a few quarters - is picking up. The seller of 'Marie Gold' and 'Bourbon' biscuits joins other domestic consumer goods makers such as Hindustan Unilever and ITC in forecasting early signs of a recovery in urban demand, aided by easing local inflation. India's annual retail inflation slowed every month in the quarter, easing to a six-year low in June at 2.1 per cent. That helped spur a "marginal uptick in consumption across both urban and rural markets," said Varun Berry, managing director and chief executive. Britannia's quarterly sales grew 9.8 per cent to ₹4,535 crore ($516.5 million). The firm had previously flagged rise in popular demand for packaged food and confectionery items such as croissants, wafers and flavoured shakes - usually more likely to be bought on impulse. But total spends rose 10.4 per cent, led by a 15 per cent jump in raw material costs. Britannia has been hiking prices to partly offset the higher costs of raw materials such as cocoa, flour and palm oil. Profits in the reported quarter came in at ₹521 crore, up 3 per cent on-year, but below analysts' average estimate of ₹570 crore rupees, according to data compiled by LSEG.

Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26
Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26

Business Standard

time2 minutes ago

  • Business Standard

Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26

Ahmedabad-based Eris Lifesciences is looking to tap opportunities in the nearly Rs 5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced the withdrawal of its insulin products from the market in April this year. 'We expect that Novo's cartridge inventory in the market will run out by October 2025. So this market opportunity is something that one can start monetising from the November–December time frame,' the company's executive director and chief executive officer (CEO), Krishnakumar Vaidyanathan, told Business Standard. He added that the timing fits Eris' plans, as the cartridge filling capability of its Bhopal unit will start becoming operational from January. Vial manufacturing has already been commissioned at the unit, with the company creating a strategic stock of insulins. This comes at a time when Eris is already the largest domestic player in insulins. The company had acquired the India formulations business of Biocon Biologics last year — including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined Rs 60 crore in revenue last year. Basalog and Insugen had combined revenues of Rs 200 crore at the time of acquisition,' he said. He added that, with this, the company's insulin franchise has become significantly larger, with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of the blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of 2025–26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to-market strategy is concerned, the company said it is already in a strong position because of its dominant presence in insulins and prior presence in the GLP market with the launch of liraglutide in September last year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to Rs 125 crore. Revenue rose to Rs 773 crore during the June quarter against Rs 720 crore in the year-ago period.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store